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external cephalic version (ecV) is associated with a moderate degree of pain. Virtual reality (VR) is a 
technology that has shown promise in offering procedural analgesia. We undertook a clinical pilot to 
assess the viability of VR to reduce pain during ECV. In an open randomised controlled trial (RCT), we 
randomised 50 women to either VR or standard care each (25 per group). Women receiving VR were 
administered VR content (Skylights) via a headset. Pre- and post-procedural measures of pain, anxiety, 
device experience and vital signs were measured. There were no significant differences between groups 
(VR/no VR) in pain scores (60.68 vs 49.76; p = 0.2), ECV success rates (80% vs 76%; p = 0.7) or anxiety 
levels. The women receiving VR had a significantly higher anticipation of pain pre-procedurally (70.0 
vs 50.0; p = 0.03). 20 (80%) of the VR women indicated that they would use VR again and 22 (88%) 
indicated they would recommend it to a friend having ECV. There were no significant differences 
between groups for side effects encountered or changes in vital signs. We have shown that using VR 
during ecV is feasible and appears safe. our results inform the design of future Rcts.
Breech presentation at term occurs in about 3–4% of pregnancies and is defined as occurring when the pelvis and/
or lower limbs of the fetus are oriented downwards. Choices in the care of women with a breech presentation at 
term include external cephalic version (ECV), caesarean section (C-Section), and vaginal breech delivery1.
In contrast to C-sections and vaginal breech delivery, ECV is a safer and less interventional approach whereby 
a fetus is manually rotated to the cephalic (head down) position by applying pressure to the maternal abdomen. 
ECV is recommended on the basis that it offers the mother a safer choice of a normal vaginal birth. It has a 60% 
success rate of cephalic presentation at the onset of labour and decreases the C-Section rate by almost 40%2.
Given the purported benefits of the procedure and the lack of alternatives, an argument could be made that 
it should be offered to all women with a breech presentation. Interestingly, between 1995 and 2001, the number 
of patients aware of the procedure had significantly increased (52.7% to 73.2%) but the number of those willing 
to consider it had decreased from 52.7% to 23.9%3. Others have suggested that concerns about pain may be an 
important factor in women declining the offer of ECV, making up to 30% of patients favour C-Section instead4,5.
Indeed, ECV is a procedure associated with a moderate degree of pain4,6–8. This was exemplified by a study 
which demonstrated median pain scores of 5.7 (IQR 2.7–6.8) in women undergoing ECV on a 10-point visual 
analogue scale8. In addition, significant improvements to success rates of the procedure have been observed when 
patients have adequate analgesia6,7,9. In addressing this, various modalities of pain relief have been trialled includ-
ing regional anaesthesia, hypnosis, and systemic opioids9. All of these are either time consuming or relatively 
invasive. Furthermore, none of them are particularly appealing to women.
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Virtual reality (VR) is an increasingly promising and affordable technological medium that is used to create 
simulated scenarios in which users are immersed and able to interact with the virtual environment (VE) through 
multisensorial stimulation10. There has been increasing interest in assessing its analgesic potential in various fields 
of medicine, especially since VR has demonstrated clinical efficacy in pain reduction whilst being well-tolerated 
by patients in a variety of settings e.g. burn wound dressing, venepuncture, and dental treatments11–16. Most 
recently, Frey et al. demonstrated significant reductions in pain for women undergoing labour whilst using VR17. 
On top of this, meta-analyses performed by Chan et al. and Mallari et al. have further substantiated this analgesic 
effect too13,18. To date, however, there has been no investigation of the use of VR in women undergoing ECV.
The precise mechanisms behind the analgesic effects of VR are still under scrutiny by researchers, though 
several theories have been proposed. For one, it is believed that VR primarily functions as a distraction mecha-
nism as a consequence of its immersive nature14. This is based on the premise that the brain has a finite capacity 
for attention towards pain which can be redirected to attenuate the degree of pain it perceives19. Alternatively, it 
has also been suggested that VR can evoke neurophysiological changes in the pain matrix of the brain thereby 
dampening its sensitivity to the sensation as well14,20,21.
objectives. Given the potential of VR to facilitate non-pharmacological analgesia, the question of its utility in 
reducing procedural pain during ECV merits consideration. This prompted us to design a pilot study to evaluate 
the use of VR as an analgesic during ECV. The objective of this pilot was to assess feasibility of concept and lay the 
foundations for an adequately powered randomised controlled trial (RCT) to test the performance of VR against 
the standard of care for all women undergoing ECV.
The primary outcomes of interest for the study involved assessing between group differences in pain scores, 
anxiety scores, physiological parameters [heart rate (HR), systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP)], women’s acceptance/feedback of the procedure, and side effects encountered between the interven-
tion (VR) and control (no VR).
The secondary outcomes were exploring associations between patient factors and the levels of pain encoun-
tered during ECV.
Methods
trial design. The study was an open label randomised controlled pilot study in 50 women. The trial had the 
approval of the Monash Health Human Research Ethics Committee (HREC/18/MonH/413). This trial was also 
registered on the Australia-New Zealand Clinical Trials Registry (ACTRN12618001004257p; registration date: 
14/06/2018) and was performed in accordance with Good Clinical Practice. Women were recruited via conveni-
ence sampling at the time of their attendance for their ECV. Written informed consent was obtained prior to the 
procedure.
Prior to commencement of the ECV, women were provided with questionnaires to assess their pre-procedural 
disposition towards pain and anxiety using 101-point numerical rating scales (NRS). This was followed by record-
ing the participant’s demographic data and their physiological parameters, heart rate (HR) and non-invasive 
blood pressure (NIBP). Following this, patients were administered terbutaline (250 micrograms) subcutaneously 
as a tocolytic.
The randomisation sequence was generated using Microsoft Excel 2018 with a 1:1 allocation using random 
block sizes of 10 and was maintained as an electronic list by AN who was independent of the trial. Following 
successful recruitment, AN was called for allocation consignment. Based on this, patients had either the inter-
vention (VR) or standard care (control) administered to them prior to the commencement of the ECV. Standard 
care entailed no provision of any form of analgesia to the patient. No blinding was performed as both patients and 
investigators were aware of the intervention administered, given the nature of VR therapy. However, at the time of 
completing the pre-procedure questionnaire, patients were unaware of their assigned group.
For the procedure, the women were placed on a flat bed with their heads elevated at a 20-degree angle with a 
pillow underneath. The ECV was then carried out by one of two skilled operators (RK/PN), both of whom had 
each performed more than 500 ECVs.
Following the procedure the number of attempt(s) and duration of ECV were recorded. An attempt was 
defined to have commenced when the operator introduced axial force to the maternal abdomen and to have 
ended when the applied force was ceased. The clinician was also asked to classify the procedure as easy, moderate 
or difficult utilising their experience with similar procedures in the past.
Post-ECV physiological parameters were also recorded for all women within 5  minutes after the procedure. 
Women from both groups were then invited to complete a questionnaire evaluating their pain (NRS), ECV 
experience, and side effects. Side effects screened for included dizziness, nausea, vomiting, tremulousness, and 
flushing.
participants. Eligible women were those with a singleton pregnancy and an ultrasound confirmed breech 
presentation at the time of the ECV.
Clinical exclusion criteria included women with multiple pregnancy, a history of prior uterine surgery, 
uterine abnormalities, contraindications to vaginal delivery, maternal cardiovascular disease, severe hyper-
tension, pre-labour rupture of membranes, placental abruption, fetal anomaly, and intra-uterine fetal death. 
Technology-related exclusion criteria encompassed prior history of sensitivity to VR technology, motion sickness, 
vertigo, seizures, epilepsy, and active nausea and vomiting.
Study settings. The study was conducted at the Monash Medical Centre, Clayton in Melbourne, Australia 
from July 2018 to March 2019. Monash Medical Centre is a university teaching hospital providing tertiary level 
obstetric care.
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intervention. For this trial, virtual reality content (VRC) was administered to the participant for the dura-
tion of the ECV through a head-mounted display (HMD), Samsung Gear VR (Samsung, San Jose, California), 
in combination with a Samsung Galaxy S8 smartphone. The VRC for the trial, “Sky Lights”, was an active form 
of VR custom designed for the study by ALO VR (Singapore). Active VRC was selected as it allows interaction 
through user input, encouraging a greater level of immersion and presence that can reduce the perception of 
noxious stimuli22–24.
In Sky Lights, the user is placed lying down in a quiet field, staring at a starry night sky with several unlit 
Chinese lanterns floating gently above. By focusing their gaze on a lantern, the user is able to set it alight, causing 
the lantern to rise upwards and away. Occasionally, as a reward for continued participation; a lit lantern will either 
set off a series of fireworks or form Lantern Festival shapes such as a dragon or a giant fish. Relaxing background 
music is also played to provide auditory stimulation. For this trial, user control was achieved by head tracking 
and lanterns were lit through triggers on either a Bluetooth hand controller or touchpad on the HMD, based on 
user preference. Orientation to the device and instructions required approximately 60  seconds and the procedure 
itself only commenced once the headset was secured onto the patient and verbal confirmation was received that 
the game had started.
For the control group, no analgesia was administered as per the standard protocols. Patients in both groups 
were counselled that they could terminate the procedure should the pain become overwhelming.
Sample size. A sample size of 25 women per arm was chosen, based on recommendations within a review by 
Whitehead et al. that focused on pilot study design and power25. These recommendations were aimed to optimise 
pilot and main trial recruitment when the standardised effect size of the main trial is uncertain but can still be 
approximated. A conservative small standardised effect size (Cohen’s  = 0.2) was implemented for this purpose, 
as demonstrated by similar VR studies in differing populations in the context of VR facilitating acute analgesia15. 
This was to generate data to inform a future pivotal RCT with a Type 2 error of 10% and Type 1 error of 5%.
Statistical methods. Raw data for the numerical variables in the study were explored for distribution 
using the Shapiro-Wilk test in tandem with visual plot analysis. Approximately normally distributed data was 
expressed as mean (±SD) and skewed data was expressed as median (IQR). Categorical variables were expressed 
as a percentage.
Key baseline characteristics and clinical data were presented as descriptive statistics for the study popula-
tion, intervention and control groups. Differences between intervention and control groups were explored using 
hypothesis testing.
For the primary outcomes, the change in physiological parameters variables (ΔSBP, ΔDBP and ΔHR) 
pre- and post-procedure were computed by the following formula (Δparameter = post-procedure parameter - 
pre-procedure parameter). Hypothesis testing was subsequently carried out to examine between group differ-
ences between intervention and control groups for the variables: pre-procedural anxiety, pre-/post-procedural 
pain, pre-/post-procedural physiological parameters and their fluctuation (Δparameter), as well as responses to 
the questionnaires.
With respect to hypothesis testing for the primary objectives, depending on the distribution, continuous 
variables were compared using either the independent samples t-test or Mann-Whitney U test. Additionally, 
the variables: post-procedure pain and change in physiological parameters (Δparameter); were compared using 
an analysis of covariance (ANCOVA) omnibus test to account for the covariates, pre-procedural anxiety and 
pre-procedural pain. Categorical data was compared using either the χ2 test of homogeneity or z-proportion test. 
For all tests, the null hypothesis was that there was no difference between the intervention and control group in 
terms of mean/median/proportion.
For the secondary outcomes, bivariate correlation was implemented to measure the strength of association 
between variables of interest and the pain scores reported by the patient during the procedure. The null hypothe-
sis was that there was no association between the variables in the population.
For all statistical tests, the assumptions of the test were met and testing carried out was two tailed. 
Furthermore, statistical significance was set at an alpha level of p < 0.05.
Statistical analysis was completed using SPSS v25.0.
Results
patient characteristics. 54 women were enrolled into the study. 50 women completed it (Fig. 1). 25 women 
were randomised to the intervention group and 25 women were randomised to the control group. The baseline 
data and clinical characteristics for the study sample, intervention and control groups are presented in Table 1. 
There were no significant differences between both control and intervention groups.
pre-intervention results. Table 2 presents the baseline participant characteristics prior to the ECV. The 
pain anticipated towards the ECV procedure was significantly higher in the intervention group than the control 
group [Median (IQR = 70 (23) vs 50 (0.5); p = 0.03]. Otherwise, there were no significant differences between 
both groups in relation to their pre-procedural anxiety levels, physiological parameters or attitudes towards the 
ECV procedure.
post-intervention results. Table 3 presents the post-intervention results.
For the intervention and control groups, there were no statistically significant differences between the pain 
score [60.68 (±21.1) vs 49.76 (±28.00; p = 0.17], ECV success rates (80% vs 76%; p = 0.73), physiological parame-
ters and change in physiological parameters pre- and post-intervention (Fig. 2). When using ANCOVA to correct 
for anticipated anxiety and pain, the adjusted means for pain scores (±standard error) between intervention and 
control were not statistically significantly different [62.0 (±4.9) vs 55.3 (±6.3); p = 0.42)]. Similarly, there was no 
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significant differences in ΔSBP [−3.37 (2.18) vs −1.33 (2.76); p = 0.58], ΔDBP [−10.45 vs −10.57; p = 0.98] and 
ΔHR [−1.10 (3.0) vs 7.23 (3.70); p = 0.09] upon correction.
Side effects were encountered in 25.5% of the study sample but was not significantly different between inter-
vention and controls (24% vs 28%; p = 0.75). These included dizziness, nausea, vomiting, tremulousness and 
flushing.
Figure 1. CONSORT 2010 Flow Diagram.
Parameters
Results for entire 
sample (n = 50)
Results for 
intervention (n = 25)
Results for control 
(n = 25) p-value
Age (years) 31.56 (±5.48)^ 32.10 (±5.50)^ 31.01 (±5.51)^ 0.49+
Gestational age (weeks) 37.21 (1.14) 37.43 (1.29) 37.00 (1.22) 0.75^
BMI (kg/m2) 28.31 (4.28) 28.82 (5.99) 27.34 (4.26) 0.26^
Parity status
Primiparity 20 (40%) 11 (55.0%) 9 (45.0%) 0.56#
Multiparity 30 (60%) 16 (53.30%) 14 (46.70%) 0.56#
AFI level (cm) 13.00 (6.77) 15.00 (8.00) 12.00 (6.35) 0.05^
Placental location
Anterior 7 (18%) 3 4 0.69~
Fundal 30 (75%) 16 14 0.65~
Posterior 3 (7%) 1 2 0.56~
Duration of ECV (s) 530 (749.50) 623 (722.00) 439 (751.50) 0.20^
Table 1. Baseline patient characteristics. ^Mean (±SD), Median (IQR), +Independent samples t- test, ^Mann 
Whitney U test, *statistically significant (p < 0.05), #Chi square test, ~z- test of proportions, BMI- Body Mass 
Index, ECV- External Cephalic Version, AFI-Amniotic Fluid Index.
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In the intervention group, 20 women (80%) indicated that they would use the VR again in a subsequent ECV 
procedure and 19 (76%) believed it should be offered as a routine part of the ECV. Twenty-two women (88%) said 
that they would recommend it to a friend undergoing ECV.
For our secondary objectives, we carried out bivariate correlation to investigate the association of participant 
and procedural characteristics with the pain scores reported (Table 4). Several variables were statistically signif-
icant and demonstrated a moderate correlation [total duration of ECV (ρ = 0.37; p = 0.01), level of anxiety felt 
pre-procedure (ρ = 0.36, p = 0.03), procedural difficulty (ρ = 0.36; p = 0.01) and pain anticipated pre-procedure 
(ρ = 0.40; p = 0.02) with pain reported by the women post-ECV.
Parameters
Results for entire 
sample (n = 50)
Results for 
intervention (n = 25)
Results for control 
(n = 25) p-value
Rate the level of pain you anticipate with 
procedure (mm) 50 (20) 70 (23) 50 (0.75) 0.03*
Rate the level of anxiety you feel about 
the procedure (mm) 50.49 (±23.98) 56.33 (±17.71) 42.81 (±29.17) 0.12
+
HR pre-procedure (bpm) 84 (19) 88 (14.50) 80 (19) 0.25^
SBP pre-procedure (mmHg) 125 (20) 125 (10) 125 (18) 0.23^
DBP pre-procedure (mmHg) 80 (15) 79.6 ± 8.15 81.6 ± 8.86 0.41+
Do you think ECV is a painful procedure?
Yes 37 21 (84.0%) 16 (64.0%) 0.11#
No 13 4 (16.0%) 9 (36.0%) 0.11#
Have you ever experienced an episode of depression in your life?
Yes 14 6 (24.0%) 8 (32.0%) 0.53#
No 36 19 (76.0%) 17 (68.0%) 0.53#
Are you anxious about the ECV?
Yes 37 21 (84.0%) 16 (64.0%) 0.11#
No 13 4 (16.0%) 9 (36.0%) 0.11#
Table 2. Patient responses to pre-procedure questionnaires and physiological parameters prior to ECV. ^Mean 
(±SD), Median (IQR), +Independent samples t-test, ^Mann-Whitney U test, *statistically significant (p < 0.05), 
#Chi square test, ~z-test of proportions.
Parameters
Results for entire 
sample (n = 50)
Results for 
intervention (n = 25)
Results for control 
(n = 25) p-value
Pain during procedure (mm) 55.20 (±25.14) 60.68 (±21.10) 49.76 (±28.00) 0.17+
SBP post-procedure (mmHg) 121.96 (±13.40) 122.72 (±13.77) 121.20 (±13.25) 0.69+
ΔSBP (mmHg) −3.50 (15) −5.00 (12.50) 0 (17.50) 0.57^
DBP post-procedure (mmHg) 72.00 (±9.90) 72.20 (±10.71) 71.80 (±9.23) 0.89+
ΔDBP (mmHg) −8.60 (±11.00) −9.40 (±10.34) −7.80 (±11.73) 0.61+
HR post-procedure (bpm) 91.94 (±12.23) 90.84 (±11.56) 93.04 (±13.0) 0.530+
ΔHR (bpm) 4.91 (±14.31) 2.16 (±12.41) 7.63 (±15.78) 0.190+
Procedural success 39 (78%) 20 (80%) 19 (76%) 0.73#
Procedural difficulty
Easy 18 (36.0%) 9 (36.0%) 9 (36.0%)
0.94#Moderate 17 (34.0%) 9 (36.0%) 8 (32.0%)
Difficult 15 (30.0%) 7 (28.0%) 8 (32.0%)
Number of attempts 2 (2) 2(2) 2(2) 0.60^
Duration of ECV (s) 530 (749.50) 623 (722.00) 439 (751.50) 0.20^
How would you rate using the device (mm)? 75 (32.50)
Side effects noted during procedure 13 (25.5%) 6 (24.0%) 7 (28.0%) 0.75#
Would you reconsider your decision to have the procedure based on the pain felt?
Yes 10 (20%) 3 (12.0%) 7 (28.0%)
0.16#
No 40 (80%) 22 (88.0%) 18 (72.0%)
Table 3. Patient responses to questionnaires post-procedure, post-ECV physiological parameters and 
comparison with pre-ECV observations. ^Mean (±SD), Median (IQR), +Independent samples t-test, ^Mann-
Whitney U test, *statistically significant (p < 0.05), #Chi square test, ~z-test of proportions, Δchange in pre- and 
post-intervention parameter.
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Discussion
This pilot study provides preliminary evidence of the feasibility of approach and acceptance from mothers for the 
novel use of VR as an analgesic during ECV. In this context, and as intended a priori, we believe there is merit in 
investigating the ability of VR to facilitate analgesia during ECV through an RCT.
Overall, this pilot did not demonstrate any significant differences in pain scores and physiological parameters 
between the intervention and control groups. This, however, should be construed in line with the motivations 
behind pilot studies in general, which is to determine feasibility-of-concept. In addition, this pilot was inade-
quately powered for hypothesis testing, thereby limiting the interpretation and generalisability of the results. 
Furthermore, the intervention group in our study had significantly higher pain anticipation in contrast to the con-
trol, which is evidenced by the moderate correlation between anticipated pain and anxiety scores pre-procedure 
with post-procedural pain scores. These anticipatory elements have been previously linked with increased per-
ceived pain scores in several studies which may have contributed to the higher non-significant pain trend in our 
intervention group26–28.
Importantly, the findings of our pilot are in stark contrast to several other higher quality studies aimed at 
assessing the utility of VR during acute pain. To date, several systematic reviews and experimental studies have 
demonstrated the analgesic efficacy of VR for management of acute pain11,13,14,29–31. In particular, the recent sys-
tematic review by Chan et al. deserves mention as they demonstrated through their meta-analysis a standardised 
mean difference of −0.49 (95% CI −0.84 to −0.41, p < 0.01) in pain reduction with the use of VR in acute pain13. 
To further reiterate this, the prospective cohort study by Tashjian et al. remains informative as well, demonstrat-
ing a 24% reduction in pain scores with VR use and a number needed to treat (NNT) of 4 to achieve an episode 
of reduced pain15. These findings suggest that VR is efficacious in facilitating acute analgesia, with the added 
advantages of being safe and cost-effective as well. Considering the shortcomings of a pilot design and the avail-
able evidence on VR’s analgesic efficacy, it would be unwarranted to discount the utility of VR in ECV without a 
formal evaluation.
One of the cornerstones of healthcare improvement, as formulated by the Institute of Healthcare 
Improvement, is with respect to the enhancement of patient experience32. In this regard, the findings of our pilot 
remain promising and in-line with other pregnancy-related studies which have demonstrated a high level of 
Figure 2. Comparison of pain and anxiety scores between the intervention and control groups pre- and post-
procedure. Statistically significant difference was defined as p < 0.05 and is denoted by (*).
Factor ρ (Spearman’s rho) p value
Age −0.10 0.51
Gestational Age 0.18 0.22
BMI 0.05 0.71
AFI level −0.30 0.84
Total duration of ECV 0.37 0.01*
Number of attempts at ECV 0.17 0.24*
Level of anxiety felt pre-procedure 0.36 0.03*
Parity status 0.20 0.17
Placental location 0.08 0.61
Procedural difficulty 0.36 0.01*
Pain anticipated pre-procedure 0.40 0.02*
Intervention status 0.24 0.10
Table 4. Correlation matrix between study variables and level of pain reported by women. *Statistically 
significant (p < 0.05).
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maternal satisfaction and acceptability for VR, with approval ratings between 77–82%17,33. This alludes to women 
being interested in and welcoming the addition of the technological medium into their pregnancy care. On this 
basis, assessing the utility of VR in enabling a better ECV experience as well as promoting greater procedural 
acceptance is an aspect which deserves formal evaluation since it could potentially influence future clinical man-
agement in an area where there is currently no analgesic standard of care34.
Our pilot also revealed side effects in approximately 25% of women. This rate is paradoxically higher in 
comparison to similar VR studies which have demonstrated side effects from the intervention to be between 
0–5%15,35,36. However, these rates were similar in both, the control and intervention groups, leading us to attribute 
this phenomena to the terbutaline employed in the study. Furthermore, despite this higher rate of side effects, 
mothers continued to partake in the VR procedure, further outlining the acceptability of the intervention.
It was found that this study has several limitations. Firstly, being a pilot, it was inadequately powered to detect 
a difference in the pain scores and physiological parameters. However, the basis of this study was to determine 
feasibility of concept, safety of VR, and to elicit participant feedback. As such, the study remains valuable in 
informing a future multicentre RCT on the issue.
Secondly, the utilisation of terbutaline for ECV is a factor which merits consideration in the context of the 
impact it may have had on the findings of our pilot. Terbutaline administration is associated with adverse side 
effects of the sympathetic activation, such as tachycardia, hypertension, nausea, vomiting, tremulousness, and 
flushing. These overlap considerably with the side effects screened for in this study and those implicated with 
VR use. This could have introduced measurement bias into the study as the adverse side effects detected in both 
groups may have been a result of the drug side effects. In addition, the terbutaline could have affected the phys-
iological parameters of the patient as well thereby limiting their usefulness as a physiological measure of pain. 
Future studies should utilise more objective measures of physiological pain, such as electrodermal activity meas-
urements, to negate this drug-related effect.
Next, due to the recruitment being sourced from a single site via convenience sampling, there is potential for 
spectrum bias to have been introduced into the study. This could be addressed by performing a multi-centre RCT 
as well.
Lastly, taking the non-significant findings of the trial into account, further information regarding the individ-
ual experience of the virtual reality interaction would have provided a more comprehensive understanding of our 
results. This includes elements such as the sense of presence in the virtual environment, appeal of the experience 
and familiarity with VR utilisation. Like several clinical evaluations of VR in the setting of acute pain, this was, 
unfortunately, not an element of our pilot evaluation. The pilot, however, highlighted the significance of acquiring 
such data and this will be incorporated into our larger scale evaluation to obtain a broad understanding of factors 
which may affect the analgesic properties of VR.
conclusions
With rising evidence supporting the clinical efficacy of VR as a form of non- pharmacological analgesia, varied 
indications for its use are increasingly being explored. This pilot serves as preliminary evidence for the feasibility, 
safety and acceptance of its utilisation during ECV. This serves to inform future controlled studies on the issue to 
systematically investigate its utility during the procedure.
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